Providing a postmortem genetic evaluation in the setting of sudden unexplained death and suspicion for long QT or Brugada syndrome
Identification of a pathogenic variant in the decedent, which may assist with risk assessment and predictive testing of at-risk family members
This test includes next-generation sequencing and supplemental Sanger sequencing to evaluate the AKAP9, ANK2,CACNA1C, CACNA2D1, CACNB2, CAV3, GPD1L, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, SCN1B, SCN3B, SCN4B, SCN5A, and SNTA1 genes.
This test is intended for use on postmortem samples (eg, formalin-fixed, paraffin-embedded [FFPE] tissue block) when whole blood is not available.
This test uses next-generation sequencing to test for variants in the AKAP9, ANK2, CACNA1C, CACNA2D1, CACNB2, CAV3, GPD1L, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, SCN1B, SCN3B, SCN4B, SCN5A, and SNTA1 genes.
This test may aid in the postmortem diagnosis of long QT or Brugada syndrome.
Identification of a pathogenic variant may assist with familial risk assessment, screening, and genetic counseling.
